Early treatment study
et al., Preprints 2020, 2020070025, doi:10.20944/preprints202007.0025.v1 (Preprint)
COVID-19 Outpatients – Early Risk-Stratified Treatment with Zinc Plus Low Dose Hydroxych loroquine and Azithromycin: A Retrospective Case Series Study
Early treatment with HC
Q+AZ+Z results in 84% lower hospitalization and 80% lower death - hospitalization OR 0.16 (p
<0.001), death OR 0.2 (p
=0.16). No cardiac side effects. Retrospective 518 patients (141 treated, 377 control).
death, ↓79.4%, p=0.13
hospitalization, ↓81.6%, p<0.001
Please send us corrections, updates, or comments.